Search by Drug Name or NDC
NDC 00409-7295-01 Potassium Phosphates 236; 224 mg/mL; mg/mL Details
Potassium Phosphates 236; 224 mg/mL; mg/mL
Potassium Phosphates is a INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hospira, Inc.. The primary component is DIBASIC POTASSIUM PHOSPHATE; MONOBASIC POTASSIUM PHOSPHATE.
Product Information
| NDC | 00409-7295 |
|---|---|
| Product ID | 0409-7295_1a84d005-2f27-4677-989c-9d975a6fa8bd |
| Associated GPIs | 79600010052030 |
| GCN Sequence Number | 001285 |
| GCN Sequence Number Description | potassium phos,m-basic-d-basic VIAL 3MMOL/ML INTRAVEN |
| HIC3 | C1P |
| HIC3 Description | PHOSPHATE REPLACEMENT |
| GCN | 03591 |
| HICL Sequence Number | 000551 |
| HICL Sequence Number Description | POTASSIUM PHOSPHATE,MONOBASIC-DIBASIC |
| Brand/Generic | Generic |
| Proprietary Name | Potassium Phosphates |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | POTASSIUM PHOSPHATE, MONOBASIC and POTASSIUM PHOSPHATE, DIBASIC |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION, CONCENTRATE |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 236; 224 |
| Active Ingredient Units | mg/mL; mg/mL |
| Substance Name | DIBASIC POTASSIUM PHOSPHATE; MONOBASIC POTASSIUM PHOSPHATE |
| Labeler Name | Hospira, Inc. |
| Pharmaceutical Class | Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC], Potassium Compounds [CS], Potassium Salt [EPC] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00409-7295-01 (00409729501)
| NDC Package Code | 0409-7295-01 |
|---|---|
| Billing NDC | 00409729501 |
| Package | 25 VIAL, SINGLE-DOSE in 1 TRAY (0409-7295-01) / 15 mL in 1 VIAL, SINGLE-DOSE (0409-7295-11) |
| Marketing Start Date | 2005-08-26 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |